Hualan Biological Engineering Inc operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hualan Biological Engineering Inc with three other
companies in this sector in China:
China Biologic Products Holdings Inc
sales of 3.09 billion Chinese Renmimbi [US$439.12 million]
of which 32%
was Human Albumin),
Tonghua Dongbao Medicines Company Limited
(2.69 billion Chinese Renmimbi [US$381.79 million]
of which 87%
was Pharmaceutical), and
Beijing Tiantan Biologic.
(2.93 billion Chinese Renmimbi [US$416.36 million]
of which 100%
was Biological products industry).
Hualan Biological Engineering Inc reported sales of 3.22 billion Chinese Renmimbi (US$456.96 million)
December of 2018.
increase of 35.8%
versus 2017, when the company's sales were 2.37 billion Chinese Renmimbi.
Sales at Hualan Biological Engineering Inc have increased during each of the previous five years
(and since 2013, sales have increased a total of 188%).
Sales of Vaccine Products saw an increase
that was more than double the company's growth rate: sales were up
183.9% in 2018, from
280.98 million Chinese Renmimbi to 797.74 million Chinese Renmimbi.